# Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

> **NCT06084689** · PHASE2 · WITHDRAWN · sponsor: **Institut Bergonié**

## Conditions studied

- Adult Soft Tissue Sarcoma
- Non Small Cell Lung Cancer
- Triple Negative Breast Cancer
- Colorectal Cancer
- Biliary Tract Cancer

## Interventions

- **DRUG:** Ezabenlimab + BI907828

## Key facts

- **NCT ID:** NCT06084689
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-14
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Discontinuation of molecule development
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084689, "Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06084689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*